. Author manuscript; available in PMC: 2017 Aug 22.

Published in final edited form as: Med Biol Eng Comput. 2008 Jun 4;46(10):1039–1049. doi: 10.1007/s11517-008-0354-7

Table 2.

Doxorubicin coverage of simulated and experimental tissues.

	Model		Experimental
	Day 4	Day 8	Day 4	Day 8
Ablated liver model (Condition A)
Area of ablated liver (mm³)	254	254	155	186
*Ablated liver over [DOX] (%)**	98.3%	98.8%	98.0%	98.3%
[DOX] in ablated liver (µg/g)^a	205 [117–430]	295 [192–398]	590 [166–1311]	1008 [361–1796]
Ablated tumor model (Condition B)
Area of ablated tumor (mm³)	254	254	343	418
Area of non-ablated tumor (mm³)	60	60	195	90
*Non-ablated tumor over [DOX] (%)**	100%	61%	87%	65%
[DOX] in non-ablated tumor (µg/g)^a	140 [78–232]	20 [8–56]	79 [30–173]	26 [7–87]

Values shown are the median concentration. Brackets contain the 25^th and 75^th percentiles.